Trial Profile
A retrospective study assessing effectiveness and cost outcomes of Everolimus plus Exemestane therapy in Metastatic Breast Cancer patients in real world
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research